Compare TG Therapeutics Inc (TGTX) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs ProShares Ultra Semiconductors — how do they compare? TG Therapeutics Inc trades at $49.61 (market cap $7.64B), while ProShares Ultra Semiconductors trades at $94.84. Which is the better fit depends on your goals.
| TGTX | USD | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $113.53 |
52-Week Low | $26.94 | $40.97 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
USD stock trades at $94.98, up 6.62% over 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows strong momentum but trades near key resistance at $93. Recent news highlights corporate developments including a dividend announcement scheduled for June 2026, though fundamental data such as P/E and revenue metrics are currently unavailable.
The outlook for USD is cautiously optimistic given technical strength, but limited fundamental data and high RSI levels suggest potential near-term volatility. Investors should weigh the bullish trend against the absence of key financial metrics and elevated technical indicators before making decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
